159 related articles for article (PubMed ID: 29889674)
1. Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency.
Tariq Z; Mudge R; Phillips S
Am J Ther; 2018; 25(6):e742-e743. PubMed ID: 29889674
[No Abstract] [Full Text] [Related]
2. Toxicity Associated with Capecitabine in Patients Suffering from Dihydropyrimidine Dehydrogenase Deficiency.
Bermejo-Pérez MJ; Galeote-Miguel AM; Rodelo-Haad LE; Alés-Díaz I; Durán-Ogalla G; Benavides-Orgaz M
Chemotherapy; 2014; 60(5-6):353-5. PubMed ID: 26330092
[TBL] [Abstract][Full Text] [Related]
3. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Kodali S; Bathini V; Rava P; Tipirneni E
J Gastrointest Cancer; 2017 Mar; 48(1):66-69. PubMed ID: 26744322
[No Abstract] [Full Text] [Related]
5. [Dihydropyrimidine dehydrogenase deficiency causes severe adverse effects of capecitabine].
Inoue H; Sato Y; Shintani S; Tanabe H; Bamba H; Komai Y; Nakamura T; Imai T; Andou A
Nihon Shokakibyo Gakkai Zasshi; 2018; 115(3):290-298. PubMed ID: 29526981
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Colon Cancer with DPD Deficiency That Showed Severe Myelosuppression by CapeOX Adjuvant Chemotherapy after Colon Resection].
Watanabe H; Arita S; Takeuchi T; Oshima Y; Koike N
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1661-1664. PubMed ID: 30449859
[TBL] [Abstract][Full Text] [Related]
7. Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
Zurayk M; Keung YK; Yu D; Hu EH
J Oncol Pharm Pract; 2019 Jan; 25(1):234-238. PubMed ID: 28950804
[TBL] [Abstract][Full Text] [Related]
8. [A case in which dihydropyrimidine dehydrogenase deficiency was strongly suspected during adjuvant chemotherapy with capecitabine for colon cancer].
Toshima T; Kodera M; Yamashita Y; Oishi M; Seshimo K; Yamamura M; Kato H; Ikeda H; Mizuno K
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1549-52. PubMed ID: 24231713
[TBL] [Abstract][Full Text] [Related]
9. [Severe capecitabine-associated toxicity in a patient carrying a mutation in the dihydropyrimidine dehydrogenase gen].
González-Haba E
Farm Hosp; 2012; 36(6):554-5. PubMed ID: 23461455
[No Abstract] [Full Text] [Related]
10. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare
van Kuilenburg ABP; Pleunis-van Empel MCH; Brouwer RB; Sijben AEJ; Knapen DG; Oude Munnink TH; van Zanden JJ; Janssens-Puister J; Dobritzsch D; Meinsma R; Meijer-Jansen J; van Dooren SJM; Vijzelaar R; Pop A; Salomons GS; Maring JG; Niezen-Koning KE
JCO Precis Oncol; 2024 May; 8():e2300599. PubMed ID: 38709992
[TBL] [Abstract][Full Text] [Related]
11. Reversible leukoencephalopathy with stroke-like presentation in a patient with 5-dihydropyrimidine dehydrogenase deficiency treated with continuous 5-fluorouracil infusion.
Li J; Lee JJ; Chu E; Baehring JM
Clin Colorectal Cancer; 2012 Sep; 11(3):215-7. PubMed ID: 22410472
[No Abstract] [Full Text] [Related]
12. [Suspected dihydropyrimidine dehydrogenase deficiency in a patient receiving capecitabine as adjuvant chemotherapy after colon resection].
Nagai K; Okuda Y; Ohara Y; Yamamoto M
Gan To Kagaku Ryoho; 2015 Jan; 42(1):127-9. PubMed ID: 25596695
[TBL] [Abstract][Full Text] [Related]
13. PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine.
Ciccolini J; Lacarelle B; Milano G
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1265-1266. PubMed ID: 29030673
[No Abstract] [Full Text] [Related]
14. Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
Hagiwara Y; Yamamoto Y; Inagaki Y; Tomisaki R; Tsuji M; Fukuda S; Fukuda S; Onoda T; Suzuki H; Niisato Y; Tange Y; Ikeda N; Yamada K; Kobayashi M; Akutsu D; Yamada T; Moriwaki T; Narasaka T; Suzuki H; Tsuchiya K
Intern Med; 2022 Aug; 61(16):2449-2455. PubMed ID: 35110482
[TBL] [Abstract][Full Text] [Related]
15. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
[TBL] [Abstract][Full Text] [Related]
16. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Lampropoulou DI; Laschos K; Amylidi AL; Angelaki A; Soupos N; Boumpoucheropoulos S; Papadopoulou E; Nanou E; Zidianakis V; Nasioulas G; Fildissis G; Aravantinos G
J Oncol Pharm Pract; 2020 Apr; 26(3):747-753. PubMed ID: 31382864
[TBL] [Abstract][Full Text] [Related]
17. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
Kigen G; Busakhala N; Njiru E; Chite F; Loehrer P
Pan Afr Med J; 2015; 21():228. PubMed ID: 26523170
[TBL] [Abstract][Full Text] [Related]
18. [Dihydropyrimidine dehydrogenase deficiency and toxicity to fluoropyrimidine].
Boisdron-Celle M; Morel A; Gamelin E
Ann Biol Clin (Paris); 2010; 68(1):27-32. PubMed ID: 20146975
[TBL] [Abstract][Full Text] [Related]
19. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
20. Unanticipated toxicity to capecitabine.
Moore S
Oncol Nurs Forum; 2009 Mar; 36(2):149-52. PubMed ID: 19273404
[No Abstract] [Full Text] [Related]
[Next] [New Search]
